📌 VIRO 2026 – Global Voices in Renal Oncology | Day 1 - Session 2
The second session of
#VIRO2026 – Global Voices in Renal Oncology continued with a practical and globally focused discussion on renal cancer care, covering treatment after first-line failure, disparities in access, diagnostic strategies, next-generation imaging, and challenges in kidney cancer clinical trials.
Maria Bourlon (
@BourlonMaite) discussed what to do after combination therapy failure in the first line, focusing on treatment considerations beyond initial therapy.
Fernando Cotait Maluf shared a Latin American perspective on renal cell carcinoma diagnosis and treatment, while Federico Losco explored the hidden burden of kidney cancer, including epidemiology, access gaps, and challenges in low- and middle-income countries.
The session then turned to diagnosis and imaging. Ying-Bei Chen (
@Unclassified1) discussed renal tumor biopsy interpretation strategies and challenges, while Janaki Sharma explored next-generation imaging in clear cell RCC.
Finally, Fed Ghali (
@FedGhali) examined common pitfalls in oncology trials within kidney cancer and beyond, bringing the session to a close with a focus on improving clinical research and evidence generation.
The session brought together clinical, diagnostic, and global perspectives to address key challenges in renal oncology and support more informed, personalized cancer care.
🔴 Live sessions available here:
nitter.net/i/broadcasts/1RJjpbVkk…
🔗 Learn more about VIRO 2026 – Global Voices in Renal Oncology:
oncodaily.com/viro-2026-glob…
#VIRO2026